SCHEDULE: Access Industries Group Discloses 19.99% Stake in OnKure Therapeutics

AI Biotechnology LLC, along with affiliated entities and Len Blavatnik, has reported beneficial ownership of 19.99% of OnKure Therapeutics' Class A Common Stock following a private placement and warrant acquisition.

Summary

• AI Biotechnology LLC (AIB), Access Industries Holdings LLC (AIH), Access Industries Management, LLC (AIM), and Len Blavatnik (collectively, the Reporting Persons) have filed a Schedule 13D indicating beneficial ownership of 9,091,532 shares of OnKure Therapeutics, Inc. Class A Common Stock, representing 19.99% of the class.
• This ownership stems from AIB's purchase on March 31, 2026, of 3,998,332 shares of Class A Common Stock at $4.15 per share and 5,640,222 pre-funded warrants at $4.1499 per warrant.
• The total number of shares considered beneficially owned includes the directly held shares and shares issuable upon exercise of the pre-funded warrants, subject to a beneficial ownership blocker.
• The calculation of the 19.99% ownership is based on 40,387,201 shares outstanding plus 5,093,200 shares issuable from warrants.
• The Reporting Persons acquired these securities as an investment and may engage in discussions with the Issuer's management and board regarding business, operations, and strategy.
• They reserve the right to acquire additional securities or dispose of existing holdings in the future, depending on market conditions and other investment considerations.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting a significant investment by a known entity but also highlighting potential future stock sales and strategic discussions.

Positives

• Significant investment by a notable investment group (Access Industries) in OnKure Therapeutics, indicating confidence in the company's potential.
• The acquisition of shares and pre-funded warrants was part of a private placement, suggesting a structured capital infusion for the company.
• AIB secured a board designation right, leading to the appointment of Dr. Liam Ratcliffe to OnKure's board, enhancing governance oversight.
• A registration rights agreement was entered into, facilitating the future resale of the acquired shares and warrant-exercisable shares.

Negatives

• The filing indicates a potential for future stock disposals by the Reporting Persons, which could create selling pressure on the stock price.
• The beneficial ownership blocker limits immediate exercise of warrants, creating a ceiling on direct ownership without prior notice.

Risks

• The Reporting Persons may dispose of all or a portion of their securities, potentially impacting the stock price.
• Future actions regarding the investment are dependent on market conditions, liquidity requirements, and other investment considerations, introducing uncertainty.
• The beneficial ownership blocker limits the immediate exercise of pre-funded warrants, with potential increases requiring 61 days' notice.

Future Outlook

The Reporting Persons intend to re-examine their investment and may acquire additional securities or dispose of existing ones based on market conditions, investment opportunities, liquidity needs, or other material considerations. They reserve the right to change their investment purpose or adopt future plans.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like Access Industries in biotechnology companies are common, often signaling a belief in the company's technology or market potential. Such filings are crucial for understanding shifts in major shareholding and potential strategic influences.

Management Changes

Related Party Transactions

• Dr. Liam Ratcliffe, appointed to the Issuer's board, is employed by Access Industries, Inc., an affiliate of AIB.

Stakeholder Impact

• Shareholders: Potential for increased market activity and scrutiny due to the significant stake held by Access Industries. Future disposals could impact share price.
• Management/Board: Increased engagement expected from the Reporting Persons regarding business, operations, and strategy. Board composition has been influenced by the investment.
• Creditors/Suppliers: No direct impact indicated, but a stable or growing company supported by significant investors is generally positive.

Next Steps

• The Reporting Persons may acquire additional securities of the Issuer.
• The Reporting Persons may dispose of all or a portion of the Issuer's securities.
• The Reporting Persons may enter into derivative transactions with institutional counterparties.
• The Issuer is obligated to file a registration statement with the SEC within 30 days of the closing of the private placement, to be declared effective within 90-120 days.

Key Dates

Recommendation

The filing indicates a significant investment by a sophisticated group, which is positive. However, the explicit reservation of rights to sell shares and the potential for future strategic shifts, coupled with the lack of specific operational or financial performance data in this filing, warrants a 'hold' recommendation pending further information on OnKure Therapeutics' business progress.

Keywords

Schedule 13D, OnKure Therapeutics, AI Biotechnology LLC, Access Industries, Len Blavatnik, Beneficial Ownership, Class A Common Stock, Pre-Funded Warrants, Private Placement, Securities Purchase Agreement, Registration Rights Agreement